Equities analysts expect that Orthofix Medical Inc (NASDAQ:OFIX) will announce earnings per share of $0.41 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Orthofix Medical’s earnings, with the highest EPS estimate coming in at $0.41 and the lowest estimate coming in at $0.40. Orthofix Medical posted earnings per share of $0.39 in the same quarter last year, which suggests a positive year-over-year growth rate of 5.1%. The company is scheduled to issue its next quarterly earnings report on Monday, April 29th.
On average, analysts expect that Orthofix Medical will report full year earnings of $1.80 per share for the current year, with EPS estimates ranging from $1.76 to $1.84. For the next year, analysts anticipate that the business will post earnings of $2.03 per share, with EPS estimates ranging from $1.99 to $2.06. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Orthofix Medical.
Orthofix Medical (NASDAQ:OFIX) last released its earnings results on Monday, February 25th. The medical device company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.13. The business had revenue of $121.08 million for the quarter, compared to analysts’ expectations of $121.90 million. Orthofix Medical had a return on equity of 11.36% and a net margin of 3.05%.
OFIX has been the topic of a number of research analyst reports. BidaskClub cut Orthofix Medical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 6th. Zacks Investment Research raised Orthofix Medical from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Wednesday, January 16th. Cantor Fitzgerald set a $66.00 target price on Orthofix Medical and gave the company a “buy” rating in a research note on Tuesday, January 8th. ValuEngine cut Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Finally, BTIG Research reissued a “neutral” rating on shares of Orthofix Medical in a research note on Tuesday, February 26th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $66.50.
In other news, insider Davide Bianchi sold 24,400 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $65.00, for a total transaction of $1,586,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.60% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its stake in shares of Orthofix Medical by 40.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 598 shares of the medical device company’s stock valued at $31,000 after buying an additional 172 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Orthofix Medical by 0.4% during the fourth quarter. Legal & General Group Plc now owns 44,270 shares of the medical device company’s stock valued at $2,325,000 after buying an additional 180 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Orthofix Medical by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 13,490 shares of the medical device company’s stock valued at $708,000 after buying an additional 296 shares during the last quarter. Texas Permanent School Fund grew its stake in shares of Orthofix Medical by 4.1% during the fourth quarter. Texas Permanent School Fund now owns 12,382 shares of the medical device company’s stock valued at $650,000 after buying an additional 483 shares during the last quarter. Finally, United Services Automobile Association grew its stake in shares of Orthofix Medical by 10.2% during the fourth quarter. United Services Automobile Association now owns 7,446 shares of the medical device company’s stock valued at $391,000 after buying an additional 687 shares during the last quarter. 96.32% of the stock is currently owned by hedge funds and other institutional investors.
OFIX traded down $0.22 during trading on Thursday, reaching $52.54. The stock had a trading volume of 179,000 shares, compared to its average volume of 126,361. The stock has a market cap of $1.05 billion, a PE ratio of 26.81 and a beta of 0.38. Orthofix Medical has a one year low of $47.79 and a one year high of $74.44.
Orthofix Medical Company Profile
Orthofix Medical, Inc engages in the provision of medical devices. It operates through the following business segments: Bone Growth Therapies, Spinal Implants, Biologics, Orthofix Extremities, and Corporate. The Bone Growth Therapies segment manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion.
Further Reading: What is Cost of Goods Sold (COGS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.